[CAS NO. 1223397-11-2] WZB117
PRODUCTS SPECIFICATIONS [1223397-11-2]
DESCRIPTION [1223397-11-2]
Overview
| MDL | MFCD24387113 |
|---|---|
| Molecular Weight | 368.31 |
| Molecular Formula | C20H13FO6 |
| SMILES | OC1=CC=CC(C(OC2=CC=CC(F)=C2OC(C3=CC(O)=CC=C3)=O)=O)=C1 |
10 Publications Citing Use of MCE
- [1]Cell Metab. 2022 Nov 11;S1550-4131(22)00490-9.
- [2]J Nanobiotechnology. 2022 Sep 15;20(1):414.
- [3]Cell Death Dis. 2022 Feb 4;13(2):118.
- [4]Acta Pharmacol Sin. 2021 Aug 30.
- [5]Lab Invest. 2022 Jan 10.
- [6]Biochim Biophys Acta Mol Cell Res. 2023 Jan 27;119434.
- [7]Photodiagnosis Photodyn Ther. 2020 Dec;32:102014.
- [8]Lab Med. 2022 Sep 15;lmac085.
- [9]Research Square Print. November 15th, 2022
- [10]Research Square Preprint. 2020 Aug.
Summary
IC50 & Target
|
GLUT1 |
In Vitro
Glucose uptake assays show that WZB117 inhibits glucose transport in cancer cells in a dose-dependent manner. The inhibition of glucose transport induced by WZB117 occurres within 1 minute after the assay started, suggesting that the inhibitory activity is likely to be via a direct and fast mechanism. Cell viability assay shows that WZB117 inhibits cancer cell proliferation with an IC 50 of approximately 10 μM. The inhibitory activity of WZB117 on cancer cell growth is also confirmed with a clonogenic assay, which also indicates that the inhibition is irreversible in nature. WZB117 treatment results in significantly more cell growth inhibition in lung cancer A549 cells than in nontumorigenic lung NL20 cells. Similar results are also observed in breast cancer MCF7 cells and their nontumorigenic MCF12A cells. When WZB117 is added to cancer cells grown under hypoxic conditions, more cell growth inhibition is observed than under normoxic conditions [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
The animal study shows that after daily intraperitoneal injection of WZB117 at 10 mg/kg body weight, the sizes of the compound-treated tumors are on average more than 70% smaller than those of the mock (PBS/DMSO)-treated tumors. Notably, 2 of the 10 compound-treated tumors disappear during the treatment and never grow back even at the end of the study. Body weight measurement and analysis reveal that the mice treated with WZB117 lost about 1 to 2 grams of body weight compared with the mock-treated mice with most of the weight loss in the fat tissue. Blood counts and analysis of mice at the end of the study show that lymphocytes and platelets are changed in the compound-treated mice compared with the vehicle-treated mice, but the cell counts remained in the normal ranges. One of the concerns for using glucose transport inhibitors is that the inhibitor might produce hyperglycemia in the treated mice [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 150 mg/mL ( 407.27 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.7151 mL | 13.5755 mL | 27.1510 mL |
| 5 mM | 0.5430 mL | 2.7151 mL | 5.4302 mL |
| 10 mM | 0.2715 mL | 1.3576 mL | 2.7151 mL |